Table III.
ADAMTS13 and its inhibitors before and after rituximab therapy.
| Study | Case no. | ADAMTS13 activity and inhibitors
|
|||
|---|---|---|---|---|---|
| Before rituximab
|
After rituximab
|
||||
| Activity | Inhibitor | Activity | Inhibitor titre | ||
| Gutterman et al (2002) | 1 | ND | ND | – | – |
| 2 | Deficiency | Yes | Increased | Decreased | |
| 3 | Deficiency | Yes | Unchanged | Decreased | |
| Chemnitz et al (2002) | 1 | Deficiency | Yes | Increased | Decreased |
| 2 | ND | ND | ND | ND | |
| Zheng et al (2003) | 1 | Deficiency | Yes | Increased | Decreased |
| Tsai and Shulman (2003) | 1 | Deficiency | Yes | Increased | Decreased |
| This report | 1 | Deficiency | Yes | Increased | Decreased |
| Overall | 8 | Deficiency: 6/6 | 6/6 | Increased: 5/6 | Decreased: 5/5 |
ND, not done. Subsequent investigation revealed the presence of ADAMTS13 deficiency because of inhibitors.